December 24th 2024
Gene therapies are revolutionizing treatment for hemophilia A and sickle cell disease; however, they are saddled with hefty price tags and limited patient populations that are impacting uptake.
Healthcare spending spurred by Part D
February 1st 2008Washington, D.C.-National healthcare spending rose 6.7% in 2006 to $2.1 trillion, just slightly faster than the previous year but still fairly stable. Overall, outlays for healthcare reflected a continued slowdown from the double-digit growth rates of the 1990s. Payments for most major health services-hospitals, physicians, nursing homes, home health services-experienced slower growth than 2005.
Read More
Bronchodilators can be effective in reducing COPD symptoms
February 1st 2008In chronic obstructive pulmonary disease (COPD), airways in the lung are partially obstructed. It's often a mixture of two diseases, chronic bronchitis and emphysema. The condition is marked by a progressive decline in lung function.
Read More
Consumer-driven pharmacy plans must focus on compliance and safety
December 1st 2007A recent survey by the Employee Benefit Research Institute found that 70% of those enrolled in consumer-directed health plans (CDHP) say that they consider costs when deciding to see a doctor or filling a prescription as compared with fewer than 40% of those in a comprehensive plan. However, the survey also found that CDHP enrollees were twice as likely to avoid, skip or delay healthcare services.
Read More
Psychotherapy, social support essential to treat depression
October 1st 2007Clinical depression is a major problem in the United States, affecting an estimated 5% to 10% of all adults. Costs for medical care and lost productivity related to depression are estimated at more than $40 billion per year.
Read More
Controlling costs may assist in improving access to biologic drugs
July 1st 2007Payers and employers can pay up to $350,000 per patient for just one year of treatment for high-cost conditions such as rheumatoid arthritis. Patients, too, share the burden, in some cases shouldering 50% of the bill in deductibles and co-pays.
Read More
Antipsychotics are the fourth largest group of medications prescribed in the United States today, with a collective cost of approximately $10 billion. Newer, second-generation medications represent 90% of the current market, and they cost considerably more than older antipsychotics.
Read More
Doctors rarely talk about drug costs in treatment plans
June 1st 2007Employers are putting more financial burden on employees in the form of higher copays and deductibles, however, in the physician's office, patients' cost concerns usually aren't discussed in advance of a particular treatment.
Read More
Effective prophylactic drugs reduce surgery infections
March 1st 2007Surgical site infections are a significant problem in hospitals today. They occur in 2% to 5% of patients who have clean operations outside the abdomen, and in up to 20% of patients with intra-abdominal procedures. They account for about 15% of hospital-acquired infections.
Read More
Drug benefit clause not easy to repeal
January 1st 2007Washington, D.C.-Although campaigning Democrats promised to repeal the "non-interference" clause in the Medicare drug benefit, making such a change may not be all that easy. Democrats could push through a straight repeal of the current provision that prevents the federal government from directly negotiating drug prices with pharmaceutical companies. Such a move, however, would not necessarily alter the program under a Republican administration that believes private drug plans can negotiate prices better than bureaucrats.
Read More
Seniors in Part D donut hole unlikely to have gap coverage
January 1st 2007Although as many as 48% of seniors were subject to some type of drug-coverage deficiency in 2006, only an estimated 4 million of the 22.5 million enrolled in Medicare drug plans were actually expected to hit the infamous donut hole. There could still be financial woes, however, for the 10.8 million Medicare beneficiaries who at least have the potential for out-of-pocket costs in the donut hole gap because they do not qualify for a subsidy, are not covered outside Part D, or did not pay for enhanced gap coverage.
Read More